Market evolution: Needles and catheters (CN 901839) — 2015–2025

Introduction

This report examines the evolution of EU trade in Needles, catheters, cannulae and the like (CN 901839) over the period 2015–2025. The product group covers medical consumables excluding syringes, tubular metal needles and suture needles — a segment that sits at the intersection of healthcare demand and advanced manufacturing.

The EU has consolidated its position as a net exporter in this segment. Exports rose from €4.98 billion in 2015 to €8.03 billion in 2025 (+61.2%), while imports grew more moderately from €4.03 billion to €6.13 billion (+51.9%). The resulting trade surplus more than doubled, from €948 million to €1.90 billion. Behind these headline figures, however, lie significant structural shifts: a reorientation of import sourcing away from the United States, the extraordinary rise of Ireland as an export hub, pandemic-era price shocks that disrupted established trade patterns, and a notable increase in export concentration even as import sources have diversified.

1. A Growing and Deepening Trade Surplus

1.1 Exports have consistently outpaced imports throughout the decade

The EU has maintained a positive trade balance in CN 901839 every year from 2015 to 2025. Over the full period, export values grew by 61.2% compared to import growth of 51.9%, widening the gap. The trade surplus reached its peak at €3.72 billion before settling at €1.90 billion in 2025 — still a 100.8% increase from the starting level.

Source: General Overview

1.2 Value growth has been driven by both volume and price increases

Export volumes rose by 22.0% (from 41,913 tonnes to 51,115 tonnes), while export unit values increased by 32.2% (from €118,882/t to €157,129/t). This indicates that the EU is not merely shipping more product — it is increasingly exporting higher-value-added items, consistent with a specialization in premium catheter and needle technologies.

On the import side, the dynamic is different. Import volumes grew only 4.3% (from 69,398 tonnes to 72,399 tonnes), but import unit values surged by 45.6% (from €58,136/t to €84,646/t). This suggests that the EU's import bill growth has been largely price-driven rather than volume-driven.

Source: General Overview

1.3 Domestic production has expanded in both volume and especially value

EU production of CN 901839 items grew from 8.71 billion units in 2015 to 9.28 billion units in 2025 (+6.5%). More strikingly, production value rose from €2.00 billion to €5.22 billion (+160.9%), reflecting the sector's shift toward higher-value, technology-intensive products. The EU's export propensity reached 145.5% in 2025 — meaning exports significantly exceed domestic production value — a hallmark of a highly integrated, re-export-oriented supply chain.

Source: Production Volumes

2. A Structural Reorientation of Trading Partners

2.1 Ireland has become the EU's dominant export engine

The most dramatic shift in EU trade for CN 901839 has been the ascent of Ireland as an export powerhouse. Irish exports in this segment surged from €1.42 billion in 2015 to €3.40 billion in 2025 — a 139.6% increase. By 2025, Ireland alone accounted for 42% of total EU exports in this product group. This reflects the country's position as a hub for global medical device and pharmaceutical manufacturing, driven by the presence of major multinationals.

The Netherlands also grew strongly (from €1.61 billion to €2.20 billion, +36.5%), while Germany remained the third-largest exporter with a more modest 24.3% increase. Belgium, notably, saw its exports decline by 30.6% over the period.

Source: Top Reporters by Value

2.2 The United States remains the EU's top extra-EU partner on both sides, but China and emerging suppliers are gaining ground

On the import side, the United States remained the largest extra-EU supplier, but its share contracted slightly (from €2.16 billion to €1.97 billion, −8.6%). Meanwhile, China's exports to the EU quintupled from €128 million to €486 million (+280.6%), and Mexico grew by 71.3% to nearly €1 billion. Malaysia also expanded significantly (+82.4%). This diversification away from US dependence is further reflected in the sharp decline of the import concentration index (HHI), which fell from 3,174 to 1,653 (−47.9%).

Source: Top Partners by Value — Imports

2.3 The United States has become an even larger destination for EU exports

On the export side, EU shipments to the United States more than doubled from €1.69 billion to €3.55 billion (+109.8%). The US absorbed a growing share of EU output, reinforcing the transatlantic nature of this trade. Switzerland (+83.5%) and China (+71.1%) also grew as export destinations. The export HHI rose from 1,529 to 2,167 (+41.7%), indicating that EU exports have become more concentrated on a smaller number of destinations — a potential vulnerability.

Source: Top Partners by Value — Exports

3. Pandemic Shocks and Their Aftermath

3.1 The COVID-19 pandemic triggered extreme price distortions in 2021

The volatility analysis reveals that the most pronounced shock events cluster around 2021 — the second year of the COVID-19 pandemic. The United Kingdom experienced a price shock of extraordinary magnitude: import prices surged by 779% relative to trend, with an abnormality score of 261. This was likely driven by post-Brexit supply chain reconfiguration compounded by pandemic-related demand surges for medical consumables. The UK also experienced a significant export price shock (shift of +96.9%).

Singapore — a re-export hub — recorded a 354.8% price shift in its exports to the EU, likely reflecting supply chain bottlenecks in Asian manufacturing.

Source: Supply Shocks

3.2 Supply chains showed varying degrees of resilience across partners

The coefficient of variation across the full period reveals which trade flows were most volatile. On the import side, Thailand (CV = 0.72) and Belarus (CV = 0.79) were the most unstable suppliers, while Malaysia (CV = 0.10) and the United States (CV = 0.18) provided relatively steady flows. On the export side, Singapore (CV = 0.71) and Tunisia (CV = 0.42) showed the highest volatility, while Türkiye (CV = 0.07) and Norway (CV = 0.08) were the most stable destinations.

These patterns suggest that while the pandemic disrupted many supply lines, certain established bilateral relationships proved more resilient.

3.3 The EU's strategic autonomy in this segment has strengthened

Despite pandemic disruptions, the EU's long-term position has improved. Net import reliance — which remains negative throughout, confirming the EU is a net exporter — moved from −71.5% to −41.7%. While this represents a reduction in the export surplus relative to production, it coincided with a sharp rise in trade intensity (from 99.6% to 121.0%) and export propensity (from 99.3% to 145.5%). This indicates that the EU's medical device sector has become more deeply integrated into global value chains, with Ireland's multinational-driven export platform playing a central role.

At the member-state level, specialisation indices confirm that Ireland (RCA = 14.53) is by far the most specialised EU member in CN 901839 exports, followed by the Netherlands (RCA = 1.81), Denmark (RCA = 1.33), and Belgium (RCA = 1.33). At the other end, Malta, Luxembourg, Portugal, Romania and Estonia show minimal specialisation in this product.

Conclusion

Over the 2015–2025 decade, the EU has consolidated its role as a global leader in needles, catheters and cannulae (CN 901839). The trade surplus has more than doubled, supported by rising export volumes and a decisive shift toward higher-value products. Ireland's emergence as the EU's dominant export platform — driven by multinational medical device manufacturers — has reshaped the intra-EU landscape, while the Netherlands and Germany maintain significant but less dynamic roles.

Externally, the EU's import sourcing has diversified substantially: the United States remains the top supplier but has lost ground, while China, Mexico and Malaysia have gained market share. This diversification has reduced import concentration. On the export side, however, the opposite trend is visible: the United States has become an even larger customer, and overall export concentration has increased — a structural vulnerability worth monitoring.

The COVID-19 pandemic in 2020–2021 left clear traces in the data, most notably through extreme price shocks in trade with the United Kingdom and Singapore. Yet the sector proved broadly resilient, with the EU leveraging the crisis period to expand its global footprint rather than retreating behind supply chain walls.

Looking forward, the combination of growing global healthcare demand, ageing populations in advanced economies, and the EU's established manufacturing base positions CN 901839 as a segment where the Union holds a durable competitive advantage — provided it manages the risks of increasing export concentration and maintains the innovation trajectory that underpins rising unit values.